Efficient immune responses against Intimin and EspB of enterohaernorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant
Efficient immune responses against Intimin and EspB of enterohaernorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant
复制标题
DOI：
10.1016/j.vaccine.2008.07.027
复制
发表时间：
2008-10-16
期刊：
影响因子：
5.5
通讯作者：
Guzman, Carlos A.
中科院分区：
文献类型：
--
作者：
Cataldi, Angel;Yevsa, Tetyana;Guzman, Carlos A.
基于来自肠出血性大肠杆菌的纯化的重组C-280 γ-Intimin和Esp 13（大肠杆菌分泌蛋白B）的粘液瘤疫苗制剂。在BALB/c小鼠中评价了与作为佐剂的TLR 2/6激动剂MALP-2（巨噬细胞活化脂肽）的聚乙二醇化衍生物共施用的大肠杆菌。鼻内接种后，观察到针对C280 γ-内膜和EspB的强烈体液和细胞免疫应答。免疫小鼠血清在体外抑制细菌溶血活性。在接受MALP-2作为佐剂的动物中主要检测到抗原特异性T细胞增殖、IL-4、IL-2和IFN-γ产生细胞以及分泌伊加。这些结果表明，C280 γ-Intimin和Esp 13是很好的候选抗原，可以掺入到针对这种重要病原体的粘膜疫苗中。(C)2008爱思唯尔有限公司保留所有权利。
Mucosal vaccine formulations based on purified recombinant C-280 gamma-Intimin and Esp13 (Escherichia coli secreted protein B) from enterohaemorragic E. coli co-administered with a pegylated derivative of the TLR2/6 agonist MALP-2 (macrophage-activating lipopeptide) as adjuvant were evaluated in BALB/c mice. After intranasal vaccination, strong humoral and cellular immune responses were observed against C280 gamma-Intimin and EspB. Sera of immunized mice inhibit bacterial haemolytic activity in vitro. Antigen-specific T-cell proliferation, 11-4, IL-2 and IFN-gamma producing cells, and secretory IgA were mostly detected in animals receiving MALP-2 as adjuvant. These results suggest that C280 gamma-Intimin and Esp13 are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen. (C) 2008 Elsevier Ltd. All rights reserved.